10.97  0.55 (5.28%)		05-12 16:00
Open: 10.14 High: 10.98 Volume: 19,636		Pre. Close: 10.42 Low: 10.14 Market Cap: 238(M)

Short term
Mid term
Targets	6-month :	15.83	1-year :	18.49
Resists	First :	13.56	Second :	15.83
Pivot price	10.19
Supports	First :	8.19	Second :	4.88
MAs	MA(5) :	10.63	MA(20) :	9.5
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0.5	Signal :	0.3
%K %D	K(14,3) :	57.7	D(3) :	56.8
RSI	RSI(14): 56.9
52-week	High :	19.57	Low :	4.88

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AARD ] has closed below upper band by 36.3%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	10.99 - 11.04	11.04 - 11.09
Low:	10.01 - 10.07	10.07 - 10.12
Close:	10.87 - 10.97	10.97 - 11.05

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Tue, 01 Apr 2025
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Fri, 14 Mar 2025
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Yahoo Finance

Sun, 23 Feb 2025
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.

Wed, 19 Feb 2025
Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com

Thu, 13 Feb 2025
Aardvark stock slides 11% following $94M IPO (AARD:NASDAQ) - Seeking Alpha

Thu, 13 Feb 2025
Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials - Fierce Biotech

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector:
Industry:
Shares Out	22 (M)
Shares Float	11 (M)
Held by Insiders	21.1 (%)
Held by Institutions	34 (%)
Shares Short	279 (K)
Shares Short P.Month	332 (K)

EPS	-0.96
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-13.44
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.4 %
Return on Equity (ttm)	-50.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.05
Qtrly Earnings Growth	0 %
Operating Cash Flow	-18 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-11.43
PEG Ratio	0
Price to Book value	-0.82
Price to Sales	0
Price to Cash Flow	-13.16

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.